Table 1 Patients’ characteristics at the time of first-line therapy
Characteristic (N = 51) | Surgery with R0 (n = 20) | Chemotherapy alone (n = 31) | P value |
|---|---|---|---|
Age at diagnosis (year) | Â | Â | 0.003* |
 Median (range) | 49(27–62) | 60(38–71) | |
Site of origin | Â | Â | 0.782 |
 Ovary | 19(95.0%) | 27(87.0%) | |
 Fallopian tube | 1(5.0%) | 2(6.5%) | |
 Peritoneum | 0(0) | 2(6.5%) | |
FIGO stage | Â | Â | 0.914 |
 I–II | 3(15.0%) | 5(16.1%) | |
 III–IV | 17(85.0%) | 26(83.9%) | |
Histology | Â | Â | 0.133 |
 Serous | 17(85.0%) | 23(74.2%) | |
 Mucinous | 2(10.0%) | 1(3.2%) | |
 Clear cell carcinoma | 0(0) | 5(16.1%) | |
 Endometrioid | 0(0) | 1(3.2%) | |
 Mixed tumor | 1(5.0%) | 0(0) | |
 Sarcocarcinoma | 0(0) | 1(3.2%) | |
Tumor grade | Â | Â | 0.454 |
 1–2 or missing | 2(10.0%) | 7(22.6%) | |
 3 | 18(90.0%) | 24(77.4%) | |
Surgical method at primary surgery | Â | Â | 0.280 |
 PDS | 18(90.0%) | 23(74.2%) | |
 NACT-IDS | 2(10.0%) | 8(25.8%) | |
Residual disease at primary surgery | Â | Â | 0.515 |
 R0 | 12(60.0%) | 22(71.0%) | |
 R1 | 7(35.0%) | 6(19.4%) | |
 R2 | 1(5.0%) | 3(9.7%) |